0 CHECKOUT

Assessment of the Japan Generics Industry

  • ID: 2196148
  • March 2012
  • Region: Japan
  • 25 Pages
  • Smart Research Insights

While Japan is the second largest pharma market globally, it has a very low penetration rate of generic drugs. The country’s government has set an ambitious goal to enhance the generics penetration to at least 30% of all ethical drugs by the end of 2012. The segment’s growth is expected to be driven by various factors such as a rapidly aging population, government initiatives to reduce healthcare spending and key drug patent expiries. The huge potential of this market has also attracted foreign players to this relatively untapped market, as they have collaborated or acquired stake in some of the domestic companies. Many Japanese hospitals are adopting the Diagnosis Procedure Combination (DPC), a flat-fee system that is promoting the penetration of generics in Japan.

Why should the report be purchased?

Our report ‘Assessment of the Japan Generics Industry’ analyzes the structure and positioning of the generics sector within the Japanese pharmaceutical industry. It highlights key trends and drivers of the generics drug industry in Japan. It analyses the key challenges being faced and the government initiatives being taken to overcome barriers and READ MORE >

Note: Product cover images may vary from those shown

1. Introduction: Japan Pharmaceutical Market

2. Japan Generic Drugs Industry: Overview
a. Performance Analysis
b. Regulatory Environment

3. Emerging Trends & Drivers

4. Industry Challenges

5. Competitive Landscape
a. Taiyo Pharmaceutical
b. Sawai Pharmaceuticals
c. TOWA Pharmaceutical
d. Nichi-Iko
e. Nippon Chemiphar

6. Future Outlook

7. Research Methodology

8. About Smart Research Insights

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: A printed copy of the report will be shipped to you.

  • Quick Help: The report will be shipped to you in CD ROM format.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS

Our Clients

  • Pfizer, Inc.
  • Sanofi S.A.
  • Abbott Laboratories Ltd.
  • Novartis AG
  • Mallinckrodt Pharmaceuticals Plc.
  • Teva Pharmaceutical Industries Ltd.